Verici Dx PLC

Company Profile

• Business description

  Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

• Contact

  19 Stanwell Road
  Avon House
  Penarth
  CardiffCF64 2EZ
  GBR

  T: +44 2920710570

  https://www.vericidx.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Diagnostics & Research

  Fiscal Year End

  31 December 2025

  Employees

  14